Tyson Foods Says It Will Eliminate Synthetic Dyes From Food Products by May
Tyson Foods CEO Donnie King made the announcement during an earnings call with investors, saying the company has been 'proactively reformulating' food products that contain any type of synthetic dyes.
King did not specify a date for when this elimination process will be completed, but noted that most of Tyson Foods' products, including its chicken nuggets, already do not include such dyes.
He added that none of the products offered through school nutrition programs contain petroleum-based synthetic dyes as ingredients.
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. praised Tyson Foods for taking swift action in response to the agency's plan to phase out those types of dyes from the nation's food supply.
'I look forward to seeing more companies follow suit and put the health of Americans first. Together, we will make America Healthy Again,' he
Related Stories
4/10/2025
5/30/2024
On April 22, HHS and the U.S. Food and Drug Administration (FDA)
FDA Commissioner Marty Makary called on food companies to use natural ingredients in their food products instead, citing concerns over the potential impacts of petrochemical dyes on children's health.
'We have a new epidemic of childhood diabetes, obesity, depression, and ADHD,' Makary said in a
Studies have linked artificial dyes with various neurobehavioral problems, according to a 2021
According to the report, the number of American children and adolescents diagnosed with ADHD has increased from an estimated 6.1 percent to 10.2 percent over the past 20 years.
The FDA in January
Previously, in March, Kennedy
'They said it's going to take us a while,' Kennedy
Zachary Stieber contributed to this report.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
20 minutes ago
- Boston Globe
US and Mexico sign deal to stop sewage release into Tijuana River
Lee Zeldin, the administrator of the Environmental Protection Agency, who traveled to Mexico to sign the memorandum of understanding with Alicia Bárcena Ibarra, Mexico's environment secretary, wrote in a statement that the countries are aiming for a 'permanent, 100% solution.' Under the deal, Mexico agreed to complete an allocation of $93 million toward sanitation infrastructure, and complete all projects by Dec. 31, 2027, the EPA said. The United States, which had withheld funds for water infrastructure improvements on the border, will release money to complete the rehabilitation of a pump station and other projects. Advertisement 'The Trump administration is proud to deliver this massive environmental and national security win for Americans in the San Diego area who have been living with this disgusting raw sewage flowing into their communities for far too long,' Zeldin said in a statement. Advertisement Bárcena Ibarra said in a statement the agreement 'strengthens collaboration to address environmental and health challenges along the northern border.' San Diego County residents have suffered acutely. The Office of the Naval Inspector General this year found that more than 1,100 Navy recruits contracted gastrointestinal illnesses after training in southern San Diego waters. And nearly half of the 40,900 households in the region have experienced health problems, including rashes and shortness of breath, that were most likely attributable to the sewage, according to the US Centers for Disease Control and Prevention. The agreement comes three months after Zeldin visited San Diego to begin negotiations with Mexico. It drew praise from local officials, including from Democrats, but some environmental advocates said more needs to be done. Jim Desmond, a Republican supervisor of the San Diego County Board of Supervisors, wrote on the social platform X that the announcement 'marks a significant step forward.' He said the federal government had previously failed to hold Mexico accountable for the sewage flowing into California. 'Our beaches must be clean, safe, and open year-round — anything less is unacceptable,' he wrote. Todd Gloria, the mayor of San Diego and a Democrat, thanked Zeldin on X and called the deal 'a huge step toward ending this crisis.' Matthew Tejada, senior vice president of environmental health for the Natural Resources Defense Council, an environmental group, called the agreement a good start. 'It's great that we're starting to roll up our sleeves' on this issue, he said. But he added that the waste-water improvements are enormous and complicated infrastructure projects that are likely going to be hit with unexpected problems, including worsening levels of runoff and sewage exacerbated by climate-fueled storms. 'These are really tough projects to implement, with really elusive outcomes,' he said. Advertisement This article originally appeared in
Yahoo
an hour ago
- Yahoo
Lawmakers Press FDA to Target Knockoff Weight-Loss Drugs
(Bloomberg) -- Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. Trump Awards $1.26 Billion Contract to Build Biggest Immigrant Detention Center in US The High Costs of Trump's 'Big Beautiful' New Car Loan Deduction Can This Bridge Ease the Troubled US-Canadian Relationship? Salt Lake City Turns Winter Olympic Bid Into Statewide Bond Boom Trump Administration Sues NYC Over Sanctuary City Policy On Friday, a group of more than 80 bipartisan lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. (Updates with statement from FDA in sixth and seventh paragraphs.) Burning Man Is Burning Through Cash Confessions of a Laptop Farmer: How an American Helped North Korea's Wild Remote Worker Scheme It's Not Just Tokyo and Kyoto: Tourists Descend on Rural Japan Elon Musk's Empire Is Creaking Under the Strain of Elon Musk A Rebel Army Is Building a Rare-Earth Empire on China's Border ©2025 Bloomberg L.P. Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
FDA Investigates Death of Boy Who Got Sarepta's Gene Therapy
US regulators said they are investigating the death of an 8-year-old boy who received a gene therapy from Sarepta Therapeutics Inc. The death occurred on June 7, according to a statement from the US Food and Drug Administration.
